{
  "id": 16223070,
  "title": "A personalized cancer vaccine could be available as soon as 2027. Here’s what we know",
  "url": "https://urgent.news/2026/10/23/a-personalized-cancer-vaccine-could-be-available-as-soon-as-2027",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-23T19:43:40.000Z",
  "source": {
    "name": "Fast Company",
    "slug": "fast-company",
    "url": "https://www.fastcompany.com/91629202/a-personalized-cancer-vaccine-could-be-available-as-soon-as-2027-heres-what-we-know"
  },
  "original_language": "en",
  "account": "A vaccine based on mRNA technology could be available as early as 2027, according to recent findings. This innovative treatment, which is currently being tested in clinical trials, has shown promising results in reducing the risk of melanoma returning or causing death. The vaccine, developed by pharmaceutical giants Merck and Moderna, is designed to target the unique genetic makeup of each patient's skin cancer. By doing so, it enhances the body's anti-tumor immune response, potentially leading to more effective treatment compared to traditional methods. In a randomized Phase 3 trial involving 1,137 patients, those who received the mRNA vaccine combined with the existing drug Keytruda experienced a 42% lower risk of recurrence or death compared to those in the control group who received Keytruda plus a placebo. The primary outcome measure of the trial was recurrence-free survival, which tracked how long patients remained cancer-free after their melanoma was surgically removed. While the news of the trial's success has led to a significant increase in Moderna's stock value, investors are still cautious about the vaccine's potential impact on other types of cancer. Nonetheless, researchers and drug developers remain optimistic about the future of personalized cancer treatment with mRNA technology.",
  "summary": "A breakthrough treatment for the deadliest form of skin cancer can cut a patient’s risk of recurrence or death nearly in half. The new scientific revelation is powered by an mRNA-based vaccine crafted with the technology behind both Pfizer and Moderna’s landmark Covid-19 shots. By using mRNA, the vaccine can be tailored to the genetic specifics of a specific patient’s skin cancer, fighting tumors…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}